首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1747036

日本血友病市場報告（按類型（血友病 A、血友病 B、血友病 C 及其他）、治療（按需治療、預防）、療法（替代療法、ITI 療法、基因療法）和地區）2025 年至 2033 年

Japan Hemophilia Market Report by Type (Hemophilia A, Hemophilia B, Hemophilia C, and Others), Treatment (On-Demand, Prophylaxis), Therapy (Replacement Therapy, ITI Therapy, Gene Therapy), and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 117 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本血友病市場規模達8.46億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到15.89億美元，2025-2033年期間的複合年成長率（CAGR）為7.3%。日本強大的醫療基礎設施、對早期診斷和有效管理的日益重視、不斷成長的研發活動、血友病治療的快速發展以及製藥公司和科技公司之間日益成長的企業合作關係，是推動市場發展的一些關鍵因素。

血友病是一種罕見的遺傳性疾病，其特徵是血液無法正常凝結，導致長時間出血。血友病是由血液中缺乏或缺乏特定凝血蛋白（例如凝血因子 VIII 或凝血因子 IX）引起的。血友病主要分為兩種：甲型血友病和B型血友病，其差異在於特定凝血因子的減少或缺失。血友病的症狀多種多樣，例如頻繁流鼻血、易瘀青、關節疼痛、輕微損傷後嚴重出血。血友病的診斷可透過身體檢查、病史評估、基因檢測、抑制物檢測以及各種實驗室檢查（例如凝血因子測定）進行。血友病的治療方法多種多樣，例如替代療法、預防性治療、基因療法、促凝血藥物、疼痛管理策略和支持性治療。這些方法有助於預防出血發作、改善生活品質、減輕疼痛並最大限度地減少關節損傷。

日本血友病市場趨勢：

日本強大的醫療基礎設施使血友病患者能夠更輕鬆地獲得診斷和治療，這是推動市場成長的主要因素之一。此外，由於日本醫療服務水平高，人們越來越重視早期診斷和有效管理，這對市場成長產生了積極影響。此外，在公共和私人投資的支持下，不斷成長的研發活動正在推動市場成長。同時，血友病護理領域的快速發展，例如開發延長半衰期的凝血因子和探索基因治療方案，正在為市場成長創造積極的前景。此外，日本人口預期壽命的增加需要對血友病等慢性疾病進行長期管理，這也推動了市場的成長。除此之外，政府為罕見疾病研究計畫提供的各種補助和激勵措施也起到了促進作用。此外，遠距醫療等技術的快速發展，使得患者（尤其是居住在偏遠地區的患者）能夠更輕鬆地諮詢專家，從而推動了市場的成長。此外，用於監測血友病相關特定變數的穿戴式健康監測技術的日益普及，也催化了市場的成長。此外，日本廣泛採用國際治療指南和方案，有助於實現護理標準化，並使治療更具可預測性和有效性，這也促進了市場的成長。同時，政府對某些以前難以獲得的治療和藥物的保險核准也給予了越來越多的支持，這也促進了市場的成長。

日本血友病市場區隔：

類型洞察：

血友病A
血友病B
血友病C
其他

治療見解：

一經請求
預防

治療見解：

替代療法
ITI 治療
基因治療

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本血友病市場目前表現如何？未來幾年將如何表現？
COVID-19 對日本血友病市場有何影響？
日本血友病市場如何按類型分類？
日本血友病市場依治療類型分類是怎樣的？
日本血友病市場依治療方法的分類是怎樣的？
日本血友病市場的價值鏈分為哪些階段？
日本血友病的關鍵促進因素和挑戰是什麼？
日本血友病市場的結構是怎麼樣的？主要參與者是誰？
日本血友病市場的競爭程度如何？

本報告回答的關鍵問題：

日本血友病市場目前表現如何？未來幾年將如何表現？
COVID-19 對日本血友病市場有何影響？
日本血友病市場如何按類型分類？
日本血友病市場依治療類型分類是怎樣的？
日本血友病市場依治療方法的分類是怎樣的？
日本血友病市場的價值鏈分為哪些階段？
日本血友病的關鍵促進因素和挑戰是什麼？
日本血友病市場的結構是怎麼樣的？主要參與者是誰？
日本血友病市場的競爭程度如何？

The Japan hemophilia market size reached USD 846.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,589.0 Million by 2033, exhibiting a growth rate (CAGR) of 7.3% during 2025-2033. The robust healthcare infrastructure in Japan, increasing focus on early diagnosis and effective management, rising research and development (R&D) activities, rapid advancements in hemophilia care, and the growing corporate partnerships between pharmaceutical companies and tech firms represent some of the key factors driving the market.

Hemophilia refers to a rare genetic disorder characterized by the inability of the blood to clot properly, leading to prolonged bleeding. It is caused by the deficiency or absence of specific clotting proteins, such as Factor VIII or Factor IX, in the blood. It primarily occurs in two forms, such as Hemophilia A and Hemophilia B, distinguished by the specific clotting factor that is either reduced or missing. Hemophilia exhibits various symptoms such as frequent nosebleeds, easy bruising, joint pain, and severe bleeding from minor injuries. It is diagnosed through physical examination, medical history evaluation, genetic testing, inhibitor testing, and various laboratory tests, such as clotting factor assays. Hemophilia is treated using multiple methods, such as replacement therapy, prophylactic treatment, gene therapy, clot-promoting medications, pain management strategies, and supportive care. They aid in preventing bleeding episodes, improving quality of life, reducing pain, and minimizing joint damage.

Japan Hemophilia Market Trends:

The robust healthcare infrastructure in Japan, facilitating easier access to diagnostics and treatment for hemophilia patients, is one of the major factors contributing to the market growth. Moreover, the increasing focus on early diagnosis and effective management of the condition due to the high standard of healthcare services in the country is positively impacting the market growth. Additionally, the rising research and development (R&D) activities, backed by public and private investments, are providing a thrust to the market growth. In line with this, rapid advancements in hemophilia care, such as the development of extended half-life clotting factors and exploration of gene therapy options, are creating a positive outlook for the market growth. Furthermore, the increasing life expectancy of the population in Japan, requiring the need for long-term management of chronic conditions like hemophilia, is providing a thrust to the market growth. In addition to this, the implementation of various government grants and incentives for research projects focused on rare diseases is acting as a growth-inducing factor. Along with this, rapid advancements such as telemedicine, which make it easier for patients to consult with specialists, especially for those living in remote areas, are boosting the market growth. Besides this, the increasing prevalence of wearable technologies for health monitoring that are customized to monitor specific variables related to hemophilia is catalyzing the market growth. Apart from this, the widespread adoption of international treatment guidelines and protocols in Japan that help standardize care and make treatment more predictable and effective is bolstering the market growth. In line with this, the growing government aid in insurance approvals for certain kinds of treatments and medications that were earlier difficult to access is fostering the market growth.

Japan Hemophilia Market Segmentation:

Type Insights:

Hemophilia A
Hemophilia B
Hemophilia C
Others

Treatment Insights:

On-Demand
Prophylaxis

Therapy Insights:

Replacement Therapy
ITI Therapy
Gene Therapy

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan hemophilia market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan hemophilia market?
What is the breakup of the Japan hemophilia market on the basis of type?
What is the breakup of the Japan hemophilia market on the basis of treatment?
What is the breakup of the Japan hemophilia market on the basis of therapy?
What are the various stages in the value chain of the Japan hemophilia market?
What are the key driving factors and challenges in the Japan hemophilia?
What is the structure of the Japan hemophilia market and who are the key players?
What is the degree of competition in the Japan hemophilia market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Hemophilia Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Hemophilia Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Hemophilia Market - Breakup by Type

6.1 Hemophilia A
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Hemophilia B
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Hemophilia C
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Others
- 6.4.1 Historical and Current Market Trends (2019-2024)
- 6.4.2 Market Forecast (2025-2033)

7 Japan Hemophilia Market - Breakup by Treatment

7.1 On-Demand
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Prophylaxis
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)

8 Japan Hemophilia Market - Breakup by Therapy

8.1 Replacement Therapy
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 ITI Therapy
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Gene Therapy
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)

9 Japan Hemophilia Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Service Offered
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Service Offered
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Service Offered
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Service Offered
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Service Offered
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Hemophilia Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis